Back

mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors

Castillo, P.; Ogando-Rivas, E.; Geffrard, H.; Pepe, A.; Liu, R.; Nguyen, D. T.; Pedro, D.; Zhang, D.; DeVries, A.; Qdaisat, S.; Karachi, A.; Rahman, M.; Weidert, F.; Milner, R.; Huang, J.; Ligon, J. A.; Silver, N.; Li, D.; Lee, J.-H.; Carrera-Justiz, S.; Mitchell, D. A.; Mendez-Gomez, H.; Sawyer, W. G.; Sayour, E. J.

2023-03-23 cancer biology
10.1101/2023.03.18.532056 bioRxiv
Show abstract

To prospectively determine whether brain tumors will respond to immune checkpoint inhibitors (ICIs), we developed a novel mRNA vaccine as a viral mimic to elucidate cytokine release from brain cancer cells in vitro. Our results indicate that cytokine signatures following mRNA challenge differ substantially from ICI responsive versus non-responsive murine tumors. These findings allow for creation of a diagnostic assay to quickly assess brain tumor immunogenicity, allowing for informed treatment with ICI or lack thereof in poorly immunogenic settings.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.